Bio-Medicines is the largest of Lilly‘s five business areas in terms of sales and accounts for nearly half of Lilly‘s mid-to-late stage pipeline assets. Unlike Lilly‘s other business areas, such as Diabetes or Oncology that focus exclusively in one therapeutic area, our business is diversified. Bio-Medicines includes the therapeutic areas of neuroscience, cardiovascular, urology, musculoskeletal and autoimmunity. Bio-Medicines is also home to Lilly‘s global marketing organisation and Lilly‘s PRA (pricing, reimbursement, and access) function, which are leading development of capabilities, solutions and tools to ensure that all of Lilly delivers unparalleled customer experiences. We are comprised of more than 20 countries, including the United States and Japan, the world‘s two largest pharmaceutical markets – along with Australia, Canada and Europe.
We have the unique role of being an incubator for Lilly, responsible for exploring and investing in new therapeutic areas and emerging fields of research. By following the science – sometimes into unchartered territory – we will continue Lilly‘s legacy of delivering innovative medicines that address unmet needs and have a profound and significant impact on people‘s lives across the world.
Across our therapeutic areas and geographies, it is our commitment to the patients we serve that unites us as a global team, sharpens our focus on the needs of our customers, and strengthens our resolve to make a difference – for patients and for Lilly. Our singular vision is to develop life-changing medicines and deliver unparalleled customer experiences.
For any further specific healthcare related enquiries, please consult your healthcare professional.